Oral glutamine protects against acute doxorubicin-induced cardiotoxicity of tumor-bearing rats

Journal of Nutrition

Volumn 140, Issue 1, 2010, Pages 44-48

  Todorova, Valentina K ^a   Kaufmann, Yihong ^b   Hennings, Leah ^a   Suzanne Klimberg, V ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CATALASE; DOXORUBICIN; ENZYME; GLUTAMINE; GLUTATHIONE; LIPID; PEROXYNITRITE; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; BREAST TUMOR; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DIET; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; ENZYME ACTIVITY; EXPERIMENTAL NEOPLASM; FEEDING; FEMALE; FISCHER 344 RAT; HEART; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HEART PROTECTION; HEART STRESS; HEART TUMOR; HISTOLOGY; LIPID PEROXIDATION; LIVER; NONHUMAN; OXIDATIVE STRESS; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; EATING; FEMALE; GLUTAMINE; GLUTATHIONE; HEART DISEASES; LIPID PEROXIDATION; MAMMARY NEOPLASMS, EXPERIMENTAL; PEROXYNITROUS ACID; RATS; RATS, INBRED F344;

RATTUS;

EID: 73649093392     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.109.113415     Document Type: Article

References (40)

1. Chlebowski RT. Adriamycin (doxorubicin) cardiotoxicity: a review. West J Med. 1979;131:364-8.
2. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185-229.
3. Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol. 1987;19:817-28.
4. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 1990;4:3076-86.
5. Olson RD, Boerth RC, Gerber J, Nies AS. Mechanism of adriamycin cardiotoxicity: evidence for oxidative stress. Life Sci. 1981;29:1393.
6. Mihm MJ, Yu F, Weinstein DM, Reiser PJ, Bauer JA. Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase. Br J Pharmacol. 2002;135:581-8.
7. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977;197:165-7.
8. L'Ecuyer T, Sanjeev S, Thomas R, Novak R, Das L, Campbell W, Heide RV. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol. 2006;291:H1273-80.
9. Mimnaugh EG, Kenedy KA, Trush MT, Sinha BK. Adriamycin enhanced membrane lipid peroxidation in isolated rat nuclei. Cancer Res. 1985;45:3296-304.
10. Julicher RH, Sterrenberg L, Bast A, Riksen RO, Koomen JM, Noordhoek J. The role of lipid peroxidation in acute doxorubicin-induced cardiotoxicity as studied in rat isolated heart. J Pharm Pharmacol. 1986;38:277.
11. Singh DK, Lippman SM. Cancer chemoprevention part 1: retinoids and carotenoids and other classic antioxidants. Oncology. 1998;12: 1643-60.
12. Pfizer Products. Doxorubicin Hydrochloride for Injection. [cited 2006]. Available from: www.pfizer.com/files/products/uspi-adriamycin.pdf.
13. Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem. 1986;261:3060-7.
14. Roth E. Nonnutritive effects of glutamine. J Nutr. 2008;138:S2025-31.
15. Labow BI, Souba WW. Glutamine. World J Surg. 2000;24:1503-13.
16. Bongers T, Griffiths RD, McArdle A. Exogenous glutamine: the clinical evidence. Crit Care Med. 2007; 35 Suppl 9:S545-52.
17. Sacks GS. Glutamine supplementation in catabolic patients. Ann Pharmacother. 1999;33:348-54.
18. Cao Y, Kennedy R, Klimberg VS. Glutamine protects against doxorubicin-induced cardiotoxicity. J Surg Res. 1999;85:178-82.
19. Todorova VK, Harms SA, Kaufmann Y, Luo S, Luo KQ, Babb KB, Klimberg VS. Glutamine supplementation reduces glutathione levels and stimulates apoptosis in DMBA-induced mammary tumors. Breast Cancer Res Treat. 2004;88:247-56.
20. Friesen C, Kiess Y, Debatin KM. A critical role of glutathione in determining apoptosis sensitivity and resistance in leukemia cells. Cell Death Differ. 2004;11 Suppl 1:S73-85.
21. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr. 1993;123:1939-51.
22. Anderson ME. Enzymatic and chemical methods for the determination of glutathione. In: Dolphin D, editor. Glutathione. 1st vol. New York: John Wiley and Sons; 1983. p. 340-65.
23. Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation. 2003;108:2423.
24. Schwartz RG, McKenzie WB, Alexander J, Sager P, D'Souza A, Manatunga A, Schwartz PE, Berger HJ, Setaro L. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82:1109-18.
25. Haq MM, Legha SS, Choksi J, Hortobagyi GN, Benjamin RS, Ewer M, Ali M. Doxorubicin-induced congestive heart failure in adults. Cancer. 1985;56:1361-5.
26. Unverferth BJ, Magorien RD, Balcerzak SP, Leier CV, Unverferth DV. Early changes in human myocardial nuclei after doxorubicin. Cancer. 1983;52:215-21.
27. Xu MF, Tang PL, Qian ZM, Ashraf M. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci. 2001;68: 889-901.
28. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest. 1980;65:128-35.
29. Hershman DL, Shao T. Anthracycline cardiotoxicity after breast cancer treatment. Oncology (Williston Park). 2009;23:227-34.
30. Folkers K, Brown R, Judy W, Morita M. Survival of cancer patients on therapy with coenzyme Q10. Biochem Biophys Res Comm. 1993;192: 241-5.
31. Myers C, Bonow R, Palmeri J, Jenkins J, Corden B, Locker G, Doroshow J, Epstein S. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol. 1983;(10 Suppl 1):53.
32. Kapadia RC, Colpoys MF, Jiang ZM, Johnson DJ, Smith RJ, Wilmore DW. Maintenance of skeletal muscle intracellular glutamine during standard surgical trauma. J Parenter Enteral Nutr. 1985;9:583-9.
33. Oehler R, Roth E. Regulative capacity of glutamine. Curr Opin Clin Nutr Metab Care. 2003;6:277-82.
34. Khogali SE, Pringle SD,Weryk BV, Rennie MJ. Is glutamine beneficial in ischemic heart disease? Nutrition. 2002;18:123-6.
35. Klimberg VS. Glutamine, cancer and its therapy. Am J Surg. 1996;172: 418-24.
36. Kaufmann Y, Todorova VK, Luo S, Klimberg VS. Effect of dietary glutamine on glutathione recycling in DMBA-breast cancer model. Nutr Cancer. 2008;60:518-25.
37. Todorova VK, Vanderpool D, Blossom S, Nwokedi E, Schaefer R, Mrak R, Klimberg VS. Oral glutamine protects against cyclophosphamide-induced cardiotoxicity and death through changes in glutathione metabolism. Nutrition. 2009;25:812-7.
38. Rubio IT, Cao Y, Hutchins LF, Westbrook KC, Klimberg VS. Effect of glutamine on methotrexate efficacy and toxicity. Ann Surg. 1998;227: 772-8.
39. Klimberg VS, Pappas AA, Nwokedi E, Jensen JC, Broadwater JR, Lang NP, Westbrook KC. Effect of supplemental dietary glutamine on methotrexate concentrations in tumors. Arch Surg. 1992;127:1317-20.
40. Wischmeyer PE. Glutamine: role in critical illness and ongoing clinical trials. Curr Opin Gastroenterol. 2008;24:190-7.